BriaCell Therapeutics Corp.
TSX:BCT.TOBiotechnology
+$0.94 today
- Market cap
- $50.02M
- Beta
- 1.53
- P/E (TTM)
- -0.3
- EPS (TTM)
- -$4.23
Volume 0.00M
Average 0.01M
BCT.TO Depreciation & Amortization
Non-cash asset write-downs added back to net income because no cash left the business.
BriaCell Therapeutics Corp.TSX: BCT.TO
Depreciation & Amortization · Q3 FY2026 · quarter ended Apr 2026
Depreciation & amortization growth accelerates
Q3 FY2026 depreciation & amortization of $33.01K rose 23.8% year over year, ahead of the -25.5% change in trailing-twelve-month depreciation & amortization. Sequentially, it rose 23.8% from the prior quarter. Over 3 fiscal years it compounded at +91.9% a year.
Context
- Depreciation & amortization increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +23.8% holds above the trailing-twelve-month pace of -25.5%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the cash flow
- Latest · FY2025
- 107.93K USD
- Year-over-year change
- +28.6%
- 4-year CAGR
- +63.1%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-07-31 | 107.93K | +28.6% |
| FY2024 | 2024-07-31 | 83.9K | +449.4% |
| FY2023 | 2023-07-31 | 15.27K | -0.0% |
| FY2022 | 2022-07-31 | 15.27K | +0.1% |
| FY2021 | 2021-07-31 | 15.26K | — |
Depreciation & Amortization vs competitors
How BCT.TO compares with its peers on the latest reported figures
No competitor Depreciation & Amortization figures are available to compare.
Cash Flow Statement
Metric | FY2021 Jul 2021 | FY2022 Jul 2022 | FY2023 Jul 2023 | FY2024 Jul 2024 | FY2025 Jul 2025 |
|---|---|---|---|---|---|
| Net Income | (13.82M) | (26.84M) | (20.3M) | (4.93M) | (26.63M) |
| Depreciation & Amortization | 15.26K | 15.27K | 15.27K | 83.9K | 107.93K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 1.97M | 3.07M | 2.19M | 1.8M | 0 |
| Change in Working Capital | (2.28M) | (391.29K) | (3.53M) | 7.05M | (1.93M) |
| Accounts Receivables | 9.94K | (11.53K) | 5.23K | (732.58K) | 742.6K |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | (1.41M) | 249.16K | 660.46K | 6.05M | (3.93M) |
| Other Working Capital | (886.38K) | (628.93K) | (4.2M) | 1.74M | 1.26M |
| Other Non-Cash Items | 6.36M | 11.66M | (2.12M) | (28.14M) | (58.73K) |
| Operating Cash Flow | (7.75M) | (12.48M) | (23.74M) | (24.13M) | (28.51M) |
| Capital Expenditures | 0 | 0 | 0 | (456.8K) | 0 |
| Acquisitions (Net) | 0 | 0 | 0 | (225K) | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | (7.74M) |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | 0 | 0 | 0 | (681.8K) | (7.74M) |
| Debt Repayment | (330.4K) | 0 | 0 | 0 | 0 |
| Common Stock Issued | 51.62M | 0 | 4M | 4.42M | 46M |
| Common Stock Repurchased | 0 | (10.17M) | (47.29K) | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 13.71M | 6.43M | 1.59K | 0 | 0 |
| Financing Cash Flow | 65M | (3.74M) | 3.95M | 4.42M | 46M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | (84.08K) |
| Net Change in Cash | 57.25M | (16.23M) | (19.79M) | (20.39M) | 9.67M |
| Free Cash Flow | (7.75M) | (12.48M) | (23.74M) | (24.58M) | (28.51M) |
BriaCell Therapeutics Corp.
TSX:BCT.TO
Intrinsic Alpha fair value
Locked
Current Price
$5.75
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.